Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsAudio – today announces the availability of a CannabisNewsAudio Broadcast titled, “Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles.”
To hear the CannabisNewsAudio version, visit: .
To read the full editorial, visit: .
Consider what [’s DehydraTECH] technology could mean for the CBD edibles space. At 15 minutes, the DehydraTECH formulation achieved 475% higher concentrations and to levels not seen or achieved by MCT. This puts DehydraTECH on par with inhalation in terms of how fast acting it is, something which has been a brass ring to the edibles industry for many years.
Rapid uptake by the body’s various tissue systems as opposed to valuable raw ingredients being flushed down the toilet because of minimal absorption — that is a huge selling point to consumers. And DehydraTECH technology provides the additional benefit of enabling lower drug-dosage quantities, an important point to consider given that “Lexaria has every reason to believe that virtually identical results would have been achieved if THC was instead the cannabinoid under examination [in the aforementioned animal studies], consistent with subjective human clinical studies Lexaria’s partners have conducted with edible THC products.”
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at .
About CannabisNewsWire (CNW)
CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.
For more information please visit .
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: .
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications:
CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office
